Michael - EMV has no need to deal with the FDA at the moment.
The project has been designated non-significant risk so the trial is being supervised at arms length by an Institutional Review Board (IRB).
It will not have to deal with the FDA until late this year or early next year afyer completion of the validation trial.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.000(0.00%) |
Mkt cap ! $153.5M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.81 | $1.77 | $88.77K | 49.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 876 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 3875 | 1 |
View Market Depth
| Last trade - 14.41pm 27/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |